Table 1. Characteristics of Studies.

AUTHOR	YEAR	DESIGN	ALLOGRAFT	SAMPLE SIZE	MEAN AGE (years)	GENDER Male/Female (%)	CMV D+/R− (%)	INDUCTION THERAPY (%)	FK (%)	CsA (%)	MMF (%)	AZT (%)	Prednisone (%)	VALGAN DAILY DOSE (MG)	CONTROL	PROPHYLAXIS DURATION (Days)	FOLLOW UP (Months)
																	Jadad Score
Paya C et al [7]	2004	Randomized	Kidney; Kidney-pancreas; Liver;Heart	364	45	74/26	100	n/a	n/a	n/a	n/a	n/a	n/a	900	Ganciclovir PO (3 g/day)	100	6 and 12
																	Jadad = 3
Khoury J et al [9]	2006	Randomized	Kidney	98	49	49/51	30	97	98	2	68	0	100	900	Preemptive	100	12
																	Jadad = 2
Said T et al [10]	2007	Randomized	Kidney	110	40	61/39	n/a	100	45	35	100	0	100	900	Ganciclovir IV (5 mg/kg/day)	14–90	6
																	Jadad = 2
Humar A et al [11]	2005	Cohort	Lung	80	49	66/44	25	29	0	90	54	36	100	900	Ganciclovir PO (3 g/day)	90	6 and 12
																	Jadad = NA
Zamora M et al [12]	2004	Cohort	Lung	230	54	55/45	21	0	0	100	0	100	100	Ganciclovir IV (30 days)+CMVIG (3 doses)+Valgan 900 mg (N = 11); 450 mg (N = 79)	Ganciclovir IV (30 days)+CMVIG (3 doses)+Acyclovir PO 800 TID	180–365	12
																	Jadad = NA
Weng F et al [13]	2007	Cohort	Kidney and Kidney-pancreas	500	46	58/62	21	55	31	61	84	0	77	450	Ganciclovir PO (3 g/day)	90	12
																	Jadad = NA
Akalin E et al [14]	2003	Case-Control	Kidney and Kidney-pancreas	129	n/a	63/37	13	47	n/a	n/a	100	0	100	450	Ganciclovir PO (3 g/day)	90	12
																	Jadad = NA
Keven K et al [15]	2004	Case-Control	Kidney and Kidney-pancreas	211	49	61/39	24	100	100	0	0	0	0	450	Ganciclovir PO (3 g/day)	90–180	12
																	Jadad = NA
Park J et al [16]	2006	Case-Control	Liver	109	50	53/47	22	0	100	0	100	0	100	450	Ganciclovir PO (3 g/day)	100	12
																	Jadad = NA